Published in:
Open Access
01-06-2011
H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
Authors:
Philippe Moris, Robbert van der Most, Isabel Leroux-Roels, Frédéric Clement, Mamadou Dramé, Emmanuel Hanon, Geert G. Leroux-Roels, Marcelle Van Mechelen
Published in:
Journal of Clinical Immunology
|
Issue 3/2011
Login to get access
Abstract
Objective
Adjuvantation of an H5N1 split-virion influenza vaccine with AS03A substantially reduces the antigen dose required to produce a putatively protective humoral response and promotes cross-clade neutralizing responses. We determined the effect of adjuvantation on antibody persistence and B- and T-cell-mediated immune responses.
Methods
Two vaccinations with a split-virion A/Vietnam/1194/2004 (H5N1, clade 1) vaccine containing 3.75–30 μg hemagglutinin and formulated with or without adjuvant were administered to groups of 50 volunteers aged 18–60 years.
Results
Adjuvantation of the vaccine led to better persistence of neutralizing and hemagglutination-inhibiting antibodies and higher frequencies of antigen-specific memory B cells. Cross-reactive and polyfunctional H5N1-specific CD4 T cells were detected at baseline and were amplified by vaccination. Expansion of CD4 T cells was enhanced by adjuvantation.
Conclusion
Formulation of the H5N1 vaccine with AS03A enhances antibody persistence and induces stronger T- and B-cell responses. The cross-clade T-cell immunity indicates that the adjuvanted vaccine primes individuals to respond to either infection and/or subsequent vaccination with strains drifted from the primary vaccine strain.